OXYBUTYNIN - Generic Drug Details

What are the generic sources for oxybutynin and what is the scope of patent protection?

Oxybutynin is the generic ingredient in eight branded drugs marketed by Barr Labs Div Teva, Allergan, Abbvie, Chartwell Rx, Ortho Mcneil Janssen, Lannett Co Inc, Pharm Assoc, Pharmobedient Cnsltg, Janssen Pharms, Accord Hlthcare, Ajanta Pharma Ltd, Amneal Pharms, Bionpharma, Impax Pharms, Osmotica Pharm Us, Pharmobedient, Rubicon Research, Unique, Zydus Pharms, Abhai Llc, Aiping Pharm Inc, Avet Lifesciences, Hibrow Hlthcare, Leading, Novast Labs, Novitium Pharma, Quantum Pharmics, Regcon Holdings, Rising, Strides Pharma, Strides Pharma Intl, Teva Pharms Usa, Tp Anda Holdings, Usl Pharma, and Watson Labs, and is included in forty-two NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for oxybutynin. One supplier is listed for this compound.

Summary for OXYBUTYNIN

US Patents:	3
Tradenames:	8
Applicants:	35
NDAs:	42
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	109
Patent Applications:	6,859
Drug Prices:	Drug price trends for OXYBUTYNIN
Drug Sales Revenues:	Drug sales revenues for OXYBUTYNIN
What excipients (inactive ingredients) are in OXYBUTYNIN?	OXYBUTYNIN excipients list
DailyMed Link:	OXYBUTYNIN at DailyMed

See drug prices for OXYBUTYNIN

See drug sales revenues for OXYBUTYNIN

Recent Clinical Trials for OXYBUTYNIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Arizona	PHASE4
Patient-Centered Outcomes Research Institute	PHASE4
Synmosa Biopharma Corp.	NA

See all OXYBUTYNIN clinical trials

Pharmacology for OXYBUTYNIN

Drug Class	Cholinergic Muscarinic Antagonist
Mechanism of Action	Cholinergic Muscarinic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for OXYBUTYNIN

G04BD	Drugs for urinary frequency and incontinence
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for OXYBUTYNIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OXYTROL	Transdermal System Extended-release	oxybutynin	3.9 mg/24 hrs	021351	1	2008-08-19

US Patents and Regulatory Information for OXYBUTYNIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Unique	OXYBUTYNIN CHLORIDE	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	206121-003	May 27, 2016	AB	RX	No	No
Accord Hlthcare	OXYBUTYNIN CHLORIDE	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	207138-003	Feb 29, 2016	AB	RX	No	No
Regcon Holdings	OXYBUTYNIN CHLORIDE	oxybutynin chloride	TABLET;ORAL	213550-001	Jul 14, 2022	AB	RX	No	No
Zydus Pharms	OXYBUTYNIN CHLORIDE	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	202332-003	Jun 26, 2017	AB	RX	No	Yes

Expired US Patents for OXYBUTYNIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	OXYTROL FOR WOMEN	oxybutynin	FILM, EXTENDED RELEASE;TRANSDERMAL	202211-001	Jan 25, 2013
Abbvie	OXYTROL FOR WOMEN	oxybutynin	FILM, EXTENDED RELEASE;TRANSDERMAL	202211-001	Jan 25, 2013
Allergan	OXYTROL	oxybutynin	FILM, EXTENDED RELEASE;TRANSDERMAL	021351-002	Feb 26, 2003
Abbvie	OXYTROL FOR WOMEN	oxybutynin	FILM, EXTENDED RELEASE;TRANSDERMAL	202211-001	Jan 25, 2013

EU/EMA Drug Approvals for OXYBUTYNIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Kentera (previously Oxybutynin Nicobrand)	oxybutynin	EMEA/H/C/000532Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.	Authorised	no	no	no	2004-06-15

OXYBUTYNIN Market Analysis and Financial Projection

Last updated: February 13, 2026

What Is the Current Market Size and Growth Trajectory for Oxybutynin?

The global oxybutynin market was valued at approximately $700 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of roughly 4.5% from 2023 to 2030. This growth reflects rising prevalence of overactive bladder (OAB), the primary indication for oxybutynin, along with increased adoption of both oral and transdermal formulations.

Key factors influencing growth include:

• Growing aging population worldwide—particularly in North America and Europe
• Increased diagnosis rates of urinary incontinence
• Expanded use in off-label conditions such as neurogenic bladder and other urological disorders
• Patent expirations and entry of generic competitors, affecting pricing dynamics

How Is the Competitive Landscape Structured?

The market comprises branded and generic manufacturers. Major players include:

• Pfizer and Sciele (historical originators)
• Actavis (now Teva), Mylan (now part of Viatris)
• Sun Pharmaceuticals
• Dr. Reddy’s Laboratories

Generic drugs currently account for over 75% of global oxybutynin sales, driven by patent expirations that occurred around 2013.

Key branded products, such as Ditropan (Pfizer), have been supplanted by generics, resulting in significant price erosion. However, branded formulations still command premiums in markets with limited generic penetration.

What Are the Pricing and Revenue Trends?

Pricing for oxybutynin varies by formulation:

• Oral tablet: Retail price ranges from $4 to $8 per month per patient
• Transdermal patch: Approximately $25 to $35 per month

The average retail price for generics has declined 50% since 2013 due to increased competition. Despite lower prices, overall revenue has increased because of higher prescription volumes.

Market share shifts favor transdermal patches, which offer better tolerability and compliance, especially in elderly populations. This form accounts for about 30% of sales in North America.

What Are the Key Drivers and Barriers in the Market?

Drivers:

• Aging demographic increases OAB prevalence (estimated at 20% of adults over 40 worldwide)
• Greater awareness of OAB treatment options
• Launch of new formulations with improved tolerability
• Insurance coverage expansion

Barriers:

• Availability of alternative drugs like mirabegron (a beta-3 adrenergic agonist)
• Pricing policies favoring generics
• Patent restrictions and regulatory hurdles in emerging markets
• Side effect profiles limiting drug usage in some patient populations

How Will the Financial Trajectory Evolve?

Projected revenue growth hinges on several factors:

• Continued patent expirations, boosting generic volumes
• Expansion into emerging markets with growing healthcare infrastructure
• The uptake of transdermal patches with higher margins
• Development of next-generation formulations with enhanced efficacy or fewer side effects

Companies investing in drug delivery innovations and expanding indications can offset generic price pressures.

What Are the Regulatory and Patent Outlooks?

Currently, oxybutynin’s primary patents have expired globally. However, patent protections for specific formulations or delivery systems (e.g., transdermal patches) remain in place in certain jurisdictions until 2025–2027.

Regulatory pathways for approval of new formulations involve approval of bioequivalence studies and safety data. The US FDA generally classifies oxybutynin as a generic drug, facilitating faster approval for new markets.

Conclusion

The oxybutynin market exhibits steady growth driven by demographic trends and increased treatment acceptance. The dominance of generics constrains pricing but sustains volume growth. Innovations in delivery systems and expanded indications may present new revenue streams.

Key Takeaways

• The global market was valued at around $700 million in 2022, with a CAGR of 4.5% expected through 2030.
• Generics dominate, comprising over 75% of sales; branded products are less prevalent.
• Transdermal patches are gaining market share owing to improved tolerability.
• Patent expirations and pricing pressures challenge profit margins but encourage volume growth.
• Future growth depends on expanding indications, emerging markets, and technological innovations.

FAQs

1. How does oxybutynin compare to newer drugs for OAB?
Oxybutynin is an established antimuscarinic agent with a well-known safety profile. Newer drugs like mirabegron are beta-3 adrenergic agonists and often have fewer anticholinergic side effects, offering alternative options.

2. What regions hold the most growth potential?
Emerging markets in Asia-Pacific and Latin America present significant growth opportunities due to increasing healthcare access and rising OAB awareness.

3. What are primary regulatory considerations?
Regulatory approval hinges on demonstrating bioequivalence for generic versions and securing patent protections for new formulations or delivery systems.

4. How will patent expirations influence the market?
Patent expirations since 2013 have led to increased generic competition, reducing prices and limiting revenue potential for branded drugs.

5. What are major factors affecting pricing?
Pricing is influenced by competition from generics, healthcare reimbursement policies, and regional drug approval and patent laws.

---

Sources:

1. MarketsandMarkets. "Overactive Bladder Therapeutics Market," 2022.
2. IQVIA. "Pharmaceutical Market Reports," 2022.
3. U.S. Food and Drug Administration (FDA). "Generic Drug Approvals and Patent Data," 2022.
4. IMS Health. "Global Prescription Data," 2022.
5. Industry interviews and patent status databases.